Very low-carb diet may improve glycemic control in type 1 diabetes with few adverse events, study finds
Researchers conducted an online survey of an international social media group of people with type 1 diabetes who follow a very low-carb diet (up to 30 g/d derived from fibrous vegetables and nuts).
Adults who were expected to have an ICU stay of at least three days and who had persistent hyperglycemia for up to six hours after admission, were receiving insulin, or both had a peripheral venous catheter placed and connected to a continuous
Between 2007 and 2014, more Medicare beneficiaries were newly prescribed metformin, dipeptidyl peptidase-4 inhibitors, and sodium-glucose cotransporter 2 inhibitors, while fewer received long-acting sulfonylureas or thiazolidinediones.
Review: Evidence is inconclusive on metabolic surgery vs. medical treatment for microvascular complications in T2DM
They also highlight the need for further RCTs assessing the effect of metabolic surgery on microvascular diabetes outcomes.
The retrospective study at a single tertiary care referral medical center compared cost-effectiveness of care from a specialized diabetes team with care from a primary service team.
The researchers found an inverse association between insulin initiation and age, and black and Hispanic participants were less likely to have insulin initiated compared with white participants.
Cardiovascular benefits of adding ezetimibe to statin therapy may be greater in patients with diabetes, study finds
Participants were randomized to receive either ezetimibe or placebo in addition to background simvastatin, and the subgroup of patients with diabetes was compared to those without the disease.
The most important predictors of the trajectory of glucose control were body mass index and levels of HbA1c and triglycerides, according to the study of registry data from the Netherlands.
The results provide further evidence that insulin pump therapy is safe and effective, even in routine diabetes care for unselected patients, according to the study authors.
Cardiovascular event rates similar between once-weekly exenatide and placebo in patients with type 2 diabetes
A limitation of the industry-funded randomized trial was the high rate of early discontinuation: 43.0% of patients on exenatide and 45.2% of those on placebo.